IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
0.630
-0.022 (-3.30%)
At close: Mar 6, 2026, 4:00 PM EST
0.620
-0.010 (-1.59%)
After-hours: Mar 6, 2026, 6:53 PM EST
IceCure Medical Employees
As of December 31, 2024, IceCure Medical had 66 total employees, including 64 full-time and 2 part-time employees. The number of employees decreased by 11 or -14.29% compared to the previous year.
Employees
66
Change (1Y)
-11
Growth (1Y)
-14.29%
Revenue / Employee
$45,076
Profits / Employee
-$231,667
Market Cap
43.45M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 66 | -11 | -14.29% |
| Dec 31, 2023 | 77 | 5 | 6.94% |
| Dec 31, 2022 | 72 | 8 | 12.50% |
| Dec 31, 2021 | 64 | 17 | 36.17% |
| Dec 31, 2020 | 47 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Accuray | 990 |
| Outset Medical | 310 |
| TELA Bio | 209 |
| Myomo | 185 |
| Cytosorbents | 149 |
| Spectral AI | 78 |
| electroCore | 73 |
| Elutia | 51 |
ICCM News
- 5 days ago - IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast Fibroadenomas - PRNewsWire
- 12 days ago - IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026 - PRNewsWire
- 16 days ago - IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense®, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation - PRNewsWire
- 24 days ago - IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense® - PRNewsWire
- 26 days ago - IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved - PRNewsWire
- 5 weeks ago - IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer - PRNewsWire
- 7 weeks ago - IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales - PRNewsWire
- 2 months ago - IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer - PRNewsWire